Indeed, we found that the RUNX3+EOMES+T-bet− subset was selectively enriched and that it dominated the CD8+ memory T cell pool in the CSF of early MS patients (p < 0.01, Figure 3A,B). Here, RUNX3 is linked to myeloid sarcoma.